Companies › Centessa Pharmaceuticals (UK)
4 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ORX750 | – | Phase 2 | Narcolepsy Type 1 | Dec 2026 |
| cleminorexton Orexin receptor agonist | HCRT | Phase 2 | Narcolepsy Type 1 | Sep 2027 |
| ORX489 | – | Phase 1 | Healthy Adult Male and Female Volunteers | Jun 2027 |
| ORX142 Tablets | – | Phase 1 | Excessive Daytime Sleepiness | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07096674 | ORX750 | Phase 2 | Narcolepsy Type 1 | Neurology | Apr 2026 |
| NCT07082829 | ORX142 Tablets | Phase 1 | Excessive Daytime Sleepiness | Neurology | Jun 2026 |
| NCT06752668 | ORX750 | Phase 2 | Narcolepsy Type 1 | Neurology | Dec 2026 |
| NCT07413666 | ORX489 | Phase 1 | Healthy Adult Male and Female Volunteers | Other | Jun 2027 |
| NCT07598708 | cleminorexton | Phase 2 | Narcolepsy Type 1 | Neurology | Sep 2027 |
Arctic Therapeutics Sundance Biosciences Teikoku Pharma USA Gateway Institute for Brain Research GEN İlaç ve Sağlık Ürünleri A.Ş.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.